CVS Health Valuation
Is CVS * undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
4/6Valuation Score 4/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of CVS * when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: CVS * (MX$951.88) is trading below our estimate of fair value (MX$2875.96)
Significantly Below Fair Value: CVS * is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for CVS *?
Other financial metrics that can be useful for relative valuation.
What is CVS *'s n/a Ratio? | |
---|---|
n/a | 0x |
n/a | n/a |
Market Cap | US$70.89b |
Key Statistics | |
---|---|
Enterprise Value/Revenue | 0.4x |
Enterprise Value/EBITDA | 8.3x |
PEG Ratio | 1.1x |
Price to Earnings Ratio vs Peers
How does CVS *'s PE Ratio compare to its peers?
Company | Forward PE | Estimated Growth | Market Cap |
---|---|---|---|
Peer Average | 28.8x | ||
CI Cigna Group | 27.2x | 17.8% | US$99.2b |
FME Fresenius Medical Care | 25x | 22.4% | €12.1b |
LH Laboratory Corporation of America Holdings | 44.6x | 20.1% | US$17.7b |
DGX Quest Diagnostics | 18.4x | 9.1% | US$15.6b |
CVS * CVS Health | 9.6x | 8.5% | Mex$70.9b |
Price-To-Earnings vs Peers: CVS * is good value based on its Price-To-Earnings Ratio (9.6x) compared to the peer average (28.8x).
Price to Earnings Ratio vs Industry
How does CVS *'s PE Ratio compare vs other companies in the Global Healthcare Industry?
Price-To-Earnings vs Industry: CVS * is good value based on its Price-To-Earnings Ratio (9.6x) compared to the Global Healthcare industry average (23.2x).
Price to Earnings Ratio vs Fair Ratio
What is CVS *'s PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
Fair Ratio | |
---|---|
Current PE Ratio | 9.6x |
Fair PE Ratio | n/a |
Price-To-Earnings vs Fair Ratio: Insufficient data to calculate CVS *'s Price-To-Earnings Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
---|---|---|---|---|---|---|---|
Current | Mex$951.88 | Mex$1,197.94 +25.8% | 16.2% | Mex$1,695.21 | Mex$990.27 | n/a | 25 |
May ’25 | Mex$1,170.00 | Mex$1,441.22 +23.2% | 10.8% | Mex$1,718.80 | Mex$1,021.07 | n/a | 26 |
Apr ’25 | Mex$1,323.67 | Mex$1,492.25 +12.7% | 7.5% | Mex$1,718.14 | Mex$1,284.44 | n/a | 26 |
Mar ’25 | Mex$1,260.00 | Mex$1,529.96 +21.4% | 7.0% | Mex$1,755.94 | Mex$1,312.70 | n/a | 25 |
Feb ’25 | Mex$1,261.50 | Mex$1,550.20 +22.9% | 7.4% | Mex$1,778.25 | Mex$1,367.89 | n/a | 24 |
Jan ’25 | Mex$1,334.20 | Mex$1,502.00 +12.6% | 8.6% | Mex$1,766.81 | Mex$1,291.13 | n/a | 24 |
Dec ’24 | Mex$1,175.00 | Mex$1,511.98 +28.7% | 9.2% | Mex$1,788.74 | Mex$1,307.15 | n/a | 23 |
Nov ’24 | Mex$1,210.00 | Mex$1,606.48 +32.8% | 10.4% | Mex$1,959.35 | Mex$1,353.73 | n/a | 23 |
Oct ’24 | Mex$1,229.00 | Mex$1,603.68 +30.5% | 10.3% | Mex$1,928.49 | Mex$1,332.41 | n/a | 24 |
Sep ’24 | Mex$1,118.00 | Mex$1,577.63 +41.1% | 9.8% | Mex$1,880.04 | Mex$1,298.94 | n/a | 24 |
Aug ’24 | Mex$1,248.00 | Mex$1,590.02 +27.4% | 12.2% | Mex$2,023.36 | Mex$1,214.01 | n/a | 23 |
Jul ’24 | Mex$1,188.00 | Mex$1,699.72 +43.1% | 16.6% | Mex$2,447.02 | Mex$1,300.51 | n/a | 24 |
Jun ’24 | Mex$1,213.00 | Mex$1,769.74 +45.9% | 16.6% | Mex$2,525.35 | Mex$1,342.14 | n/a | 23 |
May ’24 | Mex$1,315.03 | Mex$1,957.48 +48.9% | 13.3% | Mex$2,563.79 | Mex$1,541.86 | Mex$1,170.00 | 22 |
Apr ’24 | Mex$1,339.00 | Mex$2,048.77 +53.0% | 10.0% | Mex$2,587.24 | Mex$1,718.80 | Mex$1,323.67 | 21 |
Mar ’24 | Mex$1,489.84 | Mex$2,095.52 +40.7% | 9.4% | Mex$2,627.50 | Mex$1,745.54 | Mex$1,260.00 | 21 |
Feb ’24 | Mex$1,631.31 | Mex$2,208.17 +35.4% | 6.5% | Mex$2,456.17 | Mex$1,889.36 | Mex$1,261.50 | 23 |
Jan ’24 | Mex$1,755.10 | Mex$2,324.26 +32.4% | 4.9% | Mex$2,552.07 | Mex$2,080.92 | Mex$1,334.20 | 23 |
Dec ’23 | Mex$1,947.00 | Mex$2,295.57 +17.9% | 4.9% | Mex$2,515.94 | Mex$2,051.46 | Mex$1,175.00 | 23 |
Nov ’23 | Mex$1,850.00 | Mex$2,394.55 +29.4% | 5.8% | Mex$2,606.94 | Mex$2,005.34 | Mex$1,210.00 | 23 |
Oct ’23 | Mex$1,958.67 | Mex$2,452.20 +25.2% | 4.4% | Mex$2,617.29 | Mex$2,234.76 | Mex$1,229.00 | 23 |
Sep ’23 | Mex$1,999.00 | Mex$2,434.79 +21.8% | 4.4% | Mex$2,603.35 | Mex$2,222.86 | Mex$1,118.00 | 23 |
Aug ’23 | Mex$1,949.77 | Mex$2,433.45 +24.8% | 5.0% | Mex$2,633.18 | Mex$2,114.84 | Mex$1,248.00 | 24 |
Jul ’23 | Mex$1,862.51 | Mex$2,400.40 +28.9% | 5.1% | Mex$2,592.82 | Mex$2,082.42 | Mex$1,188.00 | 24 |
Jun ’23 | Mex$1,894.50 | Mex$2,329.54 +23.0% | 5.2% | Mex$2,512.03 | Mex$2,017.54 | Mex$1,213.00 | 23 |
May ’23 | Mex$1,975.23 | Mex$2,335.40 +18.2% | 4.3% | Mex$2,472.03 | Mex$2,135.83 | Mex$1,315.03 | 23 |
Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.